A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
Public ClinicalTrials.gov record NCT07532265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma
Study identification
- NCT ID
- NCT07532265
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kinaset Therapeutics Inc
- Industry
- Enrollment
- 512 participants
Conditions and interventions
Conditions
Interventions
- Frevecitinib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2026
- Primary completion
- Nov 29, 2027
- Completion
- Nov 29, 2027
- Last update posted
- Apr 19, 2026
2026 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Lancaster | California | 93534 | — |
| Research site | San Jose | California | 95117 | — |
| Research site | Brandon | Florida | 33511 | — |
| Research site | Miami | Florida | 33137 | — |
| Research site | Tampa | Florida | 33607 | — |
| Research site | Chicago | Illinois | 60612 | — |
| Research site | Kansas City | Missouri | 66160 | — |
| Research site | St Louis | Missouri | 63141 | — |
| Research site | Charlotte | North Carolina | 28277 | — |
| Research site | Pittsburgh | Pennsylvania | 15213 | — |
| Research site | Rock Hill | South Carolina | 29732 | — |
| Research site | Dallas | Texas | 75225 | — |
| Research site | Houston | Texas | 77099 | — |
| Research site | San Antonio | Texas | 78258 | — |
| Research site | Williamsburg | Virginia | 23188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07532265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07532265 live on ClinicalTrials.gov.